糖化载脂蛋白A-IV在2型糖尿病合并冠心病患者中促进动脉粥样硬化
本研究连续纳入204例无冠心病的2型糖尿病患者、515例合并冠心病的2型糖尿病患者和176名健康对照,检测高密度脂蛋白中载脂蛋白A-IV的糖化水平。结果显示apoA-IV糖化程度与冠心病存在及严重程度相关,糖化apoA-IV通过核受体NR4A3在apoE-/-小鼠中促进动脉粥样硬化。
要点
- 2型糖尿病患者apoA-IV糖化水平与冠心病存在及严重程度相关。
- 糖化apoA-IV通过NR4A3诱导炎症并促进apoE-/-小鼠动脉粥样硬化。
- 高频糖化位点突变可减弱糖化apoA-IV的促炎和促动脉粥样硬化作用。
核心结论
- 在2型糖尿病患者中,apoA-IV糖化与冠心病严重程度相关。
- 糖化apoA-IV通过NR4A3在apoE-/-小鼠中诱导动脉粥样硬化。
研究设计与样本
- 连续纳入204例无冠心病的2型糖尿病患者(I组)、515例合并冠心病的2型糖尿病患者(II组)和176名健康对照。
- 从超速离心分离的高密度脂蛋白中沉淀apoA-IV,用Western blotting光密度法测定糖化水平。
- 在37名对照、63例I组和138例II组患者中通过质谱鉴定apoA-IV的CML修饰位点。
- 将盐水或经乙二醛培养生成的糖化apoA-IV注射入apoE-/-小鼠评估动脉粥样硬化,并用于细胞实验。
主要发现
- apoA-IV糖化的相对强度和丰度与2型糖尿病患者冠心病的存在及严重程度相关(所有p < 0.05)。
- 糖化apoA-IV在体外诱导促炎反应,并通过核受体NR4A3在apoE-/-小鼠中促进动脉粥样硬化。
- 在高频糖化位点携带K-A突变的糖化apoA-IV在体外和体内均表现出比糖化apoA-IV更弱的促炎和促动脉粥样硬化作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonenzymatic glycation of apolipoproteins plays a role in the pathogenesis of the vascular complications of diabetes. OBJECTIVES: This study investigated whether apolipoprotein (apo) A-IV was glycated in patients with type 2 diabetes mellitus (T2DM) and whether apoA-IV glycation was related to coronary artery disease (CAD). The study also determined the biological effects of glycated apoA-IV. METHODS: The authors consecutively enrolled 204 patients with T2DM without CAD (Group I), 515 patients with T2DM with CAD (Group II), and 176 healthy subjects (control group) in this study. ApoA-IV was precipitated from ultracentrifugally isolated high-density lipoprotein, and its glycation level was determined based on Western blotting densitometry (relative intensity of apoA-IV glycation). ApoA-IV NƐ-(carboxylmethyl) lysine (CML) modification sites were identified by mass spectrometry in 37 control subjects, 63 patients in Group I, and 138 patients in Group II. Saline or glycated apoA-IV (g-apoA-IV) generated by glyoxal culture was injected into apoE-/- mice to evaluate atherogenesis, and was also used for the cell experiments. RESULTS: The relative intensity and the abundance of apoA-IV glycation were associated with the presence and severity of CAD in patients with T2DM (all p < 0.05). The experiments showed that g-apoA-IV induced proinflammatory reactions in vitro and promoted atherogenesis in apoE-/- mice through the nuclear receptor NR4A3. G-apoA-IV with mutations (K-A) at high-frequency glycation sites exhibited more weakened proinflammatory and atherogenic effects than did g-apoA-IV both in vitro and in vivo. CONCLUSIONS: ApoA-IV glycation is associated with CAD severity in patients with T2DM, and g-apoA-IV induces atherogenesis through NR4A3 in apoE-/- mice.
引用
- Dai Y, Shen Y, Li QR, et al. Glycated Apolipoprotein A-IV Induces Atherogenesis in Patients With CAD in Type 2 Diabetes. J Am Coll Cardiol. 2017. PMID: 29025558. doi:10.1016/j.jacc.2017.08.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。